Selution SLR, MedAlliance’s novel sirolimus-eluting balloon, has received conditional US Food and Drug Administration (FDA) investigational device exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.
This comes less than eight months after the company received its first IDE approval for Selution SLR in the treatment of below-the-knee (BTK) indications; as well as occlusive disease of the superficial femoral artery (SFA); and coronary in-stent restenosis (ISR).
Enrolment of the SELUTION SLR coronary de novo study will begin in the USA within the next few months.
This will complement the experience that the company has already gained with the SELUTION DeNOVO trial in Europe. More than 800 patients of the 3,326 planned have been enrolled in this coronary randomised controlled study comparing SELUTION SLR versus any limus drug-eluting stent (DES). The study is powered to demonstrate superiority of SELUTION SLR drug-eluting balloon (DEB) over DES in coronary de novo artery disease.
“Treatment of de novo coronary arteries with drug-eluting balloons is a breakthrough in revascularisation of coronary artery disease. The SELUTION SLR coronary de novo study is the first of its kind in the USA and will provide important data on the efficacy and safety of sirolimus-eluting balloon as a viable alternative to drug-eluting stent, leaving nothing behind post-percutaneous coronary intervention (PCI) and eliminating in-stent restenosis and related complications,” said Ron Waksman (MedStar Heart and Vascular Institute, Washington DC, USA), chairman of the MedAlliance Coronary Study Steering Committee.
“Coronary de novo lesions are the largest potential opportunity for use of DEBs: the data have shown clearly that DES do not work well in small vessels, long, or bifurcated lesions or in patients with diabetes or risk of high bleeding complications. These patients represent 60% of all patients currently treated with DES, who may now benefit from this exciting new DEB technology,” added Jeffrey B Jump, chairman and CEO of MedAlliance.
Selution SLR was awarded CE mark approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
MedAlliance’s DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the antirestenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days.
Selution SLR 014 PTCA is commercially available in Europe, Asia, the Middle East and the Americas (outside USA) and most other countries where the CE mark is recognised. Over 10,000 coronary units have already been used for patient treatment in routine clinical practice or as part of clinical trials.